Dupilumab Surpasses Omalizumab for Type‑2 Respiratory Disease: Converging Evidence from a Head‑to‑Head RCT, Real‑World US Data, and a Target‑Trial Emulation
Posted inAllergy & Immunology news Respiratory

Dupilumab Surpasses Omalizumab for Type‑2 Respiratory Disease: Converging Evidence from a Head‑to‑Head RCT, Real‑World US Data, and a Target‑Trial Emulation

Three complementary studies—EVEREST (head‑to‑head RCT), the US ADVANTAGE real‑world study, and a target‑trial emulation—consistently show greater reductions in nasal polyp burden, smell loss, asthma exacerbations, and systemic steroid use with dupilumab versus omalizumab in type‑2 respiratory disease.